keyword
https://read.qxmd.com/read/38817694/the-role-of-vertebral-augmentation-procedures-in-the-management-of-multiple-myeloma
#1
REVIEW
Nishanth Thalambedu, Mudassar Kamran, Samer Al-Hadidi
Approximately 90% of patients with multiple myeloma experience significant pain from osseous involvement during their lifetime. Untreated osseous involvement results in vertebral compression fractures, leading to negative consequences for quality of life. Vertebral augmentation procedures, including percutaneous vertebroplasty and kyphoplasty, offer better and faster pain control and likely lower morbidity compared with non-operative interventions. Our review provides an up-to-date summary of the indications, contraindications, timing, outcomes, and potential complications of vertebral augmentation procedures to guide practicing oncologists in effectively managing bone disease in patients with multiple myeloma...
2024: Clinical hematology international
https://read.qxmd.com/read/38806885/prognostic-value-of-visual-impetus-criteria-and-metabolic-tumor-burden-at-baseline-18-f-fdg-pet-ct-in-patients-with-newly-diagnosed-multiple-myeloma
#2
JOURNAL ARTICLE
Silvano Marchiori, François Cousin, Iraklis Papadopoulos, Claire Bernard, Marie Thys, Bernard De Prijck, Michelle Pirotte, Anne-Françoise Donneau, Roland Hustinx, Jo Caers, Nadia Withofs
BACKGROUND: 2-[18 F]fluoro-2-deoxy-D-glucose ([18 F]FDG) positron emission tomography combined with low-dose computed tomography (PET/CT) can be used at diagnosis to identify myeloma-defining events and also provides prognostic factors. The aim of this study was to assess the prognostic significance of baseline [18 F]FDG PET/CT visual IMPeTUs (Italian myeloma criteria for PET Use)-based parameters and/or total metabolic tumor volume (TMTV) in a single-center population of patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation...
May 28, 2024: EJNMMI Research
https://read.qxmd.com/read/38797190/pembrolizumab-and-low-dose-single-fraction-radiotherapy-for-patients-with-relapsed-or-refractory-multiple-myeloma-a-prospective-single-centre-single-group-open-label-phase-2-pilot-trial-in-the-usa
#3
JOURNAL ARTICLE
Mohammad K Khan, Tahseen H Nasti, Joshua Y Qian, Troy J Kleber, Jeffrey M Switchenko, Jonathan L Kaufman, Ajay J Nooka, Madhav V Dhodapkar, Zachary S Buchwald, Daby Obiekwe, Sagar Lonial, Rafi Ahmed
BACKGROUND: Currently, the use of radiotherapy alone for people with multiple myeloma is limited to palliation of pain, pending fracture, and control of spinal-cord compression. Single immune-checkpoint inhibitors, such as anti-programmed death-1 (anti-PD1), have not been successful. We aimed to evaluate the activity and safety of the combination of pembrolizumab and low-dose, single-fraction, hypofractionated radiotherapy to treat patients with relapsed or refractory multiple myeloma...
May 23, 2024: Lancet Haematology
https://read.qxmd.com/read/38733817/current-status-of-bispecific-antibodies-and-car-t-therapies-in-multiple-myeloma
#4
REVIEW
Wojciech Szlasa, Jarosław Dybko
Multiple myeloma (MM), a malignancy of plasma cells, is an incurable disease that is characterized by the neoplastic proliferation of plasma cells leading to extensive skeletal destruction. This includes osteolytic lesions, osteopenia, and pathologic fractures. MM is clinically manifested through bone pain, renal insufficiency, hypercalcemia, anemia, and recurrent infections. Its prevalence and the need for effective treatment underscore the importance of this research. Recent advancements in MM therapy have been significant, particularly with the integration of daratumumab into first-line treatments...
May 10, 2024: International Immunopharmacology
https://read.qxmd.com/read/38717495/assessment-of-inter-and-intraobserver-agreement-for-meta-score-in-distinguishing-osteoporotic-from-multiple-myeloma-vertebral-fractures
#5
JOURNAL ARTICLE
Eduardo Henrique Chiovato Abdala, João Pedro Almeida E Oliveira, Mariana Demétrio de Sousa Pontes, Ângelo Augusto Bongiolo Ganeo, Marcelo Henrique Nogueira-Barbosa, Carlos Fernando P S Herrero
PURPOSE: To conduct an independent assessment of inter- and intraobserver agreement for the META score as a tool for differentiating osteoporotic vertebral fractures and multiple myeloma vertebral fractures. METHODS: This is a retrospective observational study. The magnetic resonance imaging analysis was made by two independent spinal surgeons. We designated a Subjective assessment, in which the surgeon should establish a diagnostic classification for each vertebral fracture based on personal experience: secondary to osteoporosis, categorized as a benign vertebral fracture (BVF), or attributed to multiple myeloma, categorized a malign vertebral fracture (MVF)...
May 8, 2024: European Spine Journal
https://read.qxmd.com/read/38709580/multiple-myeloma
#6
REVIEW
Mary C Vrtis
Multiple myeloma (MM) is a cancer that arises from plasma cells in bone marrow. Approximately 35,730 Americans received a new diagnosis and MM will claim the lives of an estimated 12,590 people in 2023. Complications of the disease process include anemia, leukopenia, thrombocytopenia, renal failure, severe pain, bone loss, and hypercalcemia. Patients with MM have a high risk for pathological fractures. For most forms of MM there are effective treatments that may result in long-term remission using multi-drug regimens...
May 2024: Home Healthcare Now
https://read.qxmd.com/read/38689668/complex-pathological-femoral-fracture-in-a-multiple-myeloma-patient-undergoing-intertrochanteric-fixation-a-case-report
#7
Ameer Khan, Daniel K Kyeremateng, Zeeshan A Khan, Muhammad S Tariq, Munir Khan
Pathological fractures commonly occur in patients with metastatic bone diseases, particularly multiple myeloma. The current optimal management for metastatic pathological lesions affecting the proximal femur is surgical intervention. Surgical planning and appropriate use of imaging modalities are pivotal in the appropriate treatment of pathological fractures. Impending fractures create added layers of complexity in the decision-making process. The appropriateness of different surgical interventions involves a multi-disciplinary approach and the importance of holistic healthcare is paramount in these circumstances...
April 2024: Curēus
https://read.qxmd.com/read/38665945/outcomes-of-percutaneous-vertebroplasty-in-multiple-myeloma-a-tertiary-neurosciences-experience-with-long-term-follow-up
#8
JOURNAL ARTICLE
Hannah E Holmes, Vartan Balian, Saminderjit Kular, Ruth Batty, Daniel J A Connolly, Andrew Chantry, Andrew Martin
BACKGROUND: Multiple myeloma is diagnosed in 5,800 people in the United Kingdom (UK) each year with up to 64% having vertebral compression fractures at the time of diagnosis. Painful vertebral compression fractures can be of significant detriment to patients' quality of life. Percutaneous vertebroplasty aims to provide long-term pain relief and stabilize fractured vertebrae. METHODS AND MATERIALS: Data was collected from all cases of percutaneous vertebroplasty performed on patients with multiple myeloma from November 2017 to January 2019...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38577249/high-rate-of-progression-to-symptomatic-multiple-myeloma-in-patients-with-smoldering-myeloma-and-isolated-osteoporotic-vertebral-fracture
#9
JOURNAL ARTICLE
Kevin Chevalier, Sabrina Hamroun, Samuel Bitoun, Julien Henry, Christian Roux, Karine Briot, Rakiba Belkhir, Xavier Mariette, Raphaèle Seror
Multiple myeloma (MM) frequently causes vertebral fractures (VF). Some are lytic lesions and others have the aspect of benign osteoporotic fractures not requiring anti-myeloma treatment. We explored outcome of these patients with smoldering myeloma (SM) and osteoporotic VF. In this retrospective bi-centric study, patients were identified using a systematic keyword search on electronic medical records. Patients with SM and isolated VF of osteoporotic aspect without indications for myeloma-specific therapy were included...
June 2024: Bone Reports
https://read.qxmd.com/read/38546066/impact-of-genetic-polymorphisms-in-nf-%C3%A4-b2-and-traf3-genes-on-response-to-bortezomib-based-therapy-in-multiple-myeloma-patients
#10
JOURNAL ARTICLE
Nidhi Sood, Abdoul Hamide, Biswajit Dubashi, Yadav Nisha, Jayanthi Mathaiyan, A K Munirajan, Prasanth Ganesn, Smita Kayal
BACKGROUND: Multiple myeloma (MM), being the second most common hematological malignancy, has garnered significant attention. The ubiquitin proteasomal pathway (UPP), crucial for normal cell function, plays a pivotal role in myeloma pathophysiology, especially with the advent of bortezomib (BTZ). Dysregulation of the UPP has implications ranging from developmental abnormalities to cancer. OBJECTIVES: This study aimed to delineate the clinical characteristics of newly diagnosed multiple myeloma patients and investigate the influence of single nucleotide polymorphisms (SNPs) in NF-ĸB2 and TRAF3 genes on the risk and treatment response to bortezomib-based chemotherapy...
March 1, 2024: Asian Pacific Journal of Cancer Prevention: APJCP
https://read.qxmd.com/read/38524572/unusual-body-weight-loss-due-to-primary-hyperparathyroidism-a-case-study-with-literature-review
#11
Yan-Yu Lin, Shuen-Fu Weng, Ting-Teng Yang, Yi-Wei Lee, Ju-Han Liu, Yu-Shan Hsieh
Brown tumors (osteitis fibrosa cystica) are rare pathognomonic signs that occur in patients with primary hyperparathyroidism (PHPT). Brown tumors can exist in multiple bones and can easily be misdiagnosed as a metastatic tumor or multiple myeloma. It is also localized in the forearm, humerus, and leg. The symptoms of hypercalcemia, pathologic fracture, and bodyweight loss may increase the diagnostic difficulty of brown tumors because multiple myeloma and bone metastasis also show the same symptoms. We studied a 68-year-old woman who had experienced unusual bodyweight loss in the past 6 months (56kg-40kg) and bone pain...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38499893/geriatric-chronic-recurrent-multifocal-osteomyelitis-crmo-mimicking-multifocal-multiple-myeloma-a-first-in-an-octogenarian
#12
JOURNAL ARTICLE
Jonathan Sgaglione, Andrew Muran, Matthew Rhode, Howard J Goodman, Morris C Edelman, Suhail Ahmed Shah, Andrew S Greenberg, Shachar Kenan
Chronic recurrent multifocal osteomyelitis (CRMO), an autoinflammatory bone disorder characterized by non-bacterial osteomyelitis causing recurrent multifocal bone lesions, is a well-known, yet uncommon pediatric condition that rarely affects adults; to date, it has never been diagnosed over the age of 75. The following report will discuss the first octogenarian diagnosed with CRMO and therefore represents an exceptionally rare presentation of a rare disease. An 83-year-old woman presented with progressive right shoulder, forearm, and hip pain, with associated weight loss and global weakness, requiring a wheelchair for mobility...
March 19, 2024: Skeletal Radiology
https://read.qxmd.com/read/38457822/challenges-of-fracture-risk-assessment-in-asian-and-black-women
#13
JOURNAL ARTICLE
Joan C Lo, Malini Chandra, Wei Yang, Nailah Thompson, Catherine Lee, Mohan Ramaswamy, Mehreen Khan, Amber Wheeler
OBJECTIVES: Bone mineral density (BMD) and fracture risk calculators (eg, the Fracture Risk Assessment Tool [FRAX]) guide primary prevention care in postmenopausal women. BMD scores use non-Hispanic White (NHW) reference data for T-score classification, whereas FRAX incorporates BMD, clinical risk factors, and population differences when calculating risk. This study compares findings among Asian, Black, and NHW women who underwent osteoporosis screening in a US health care system. STUDY DESIGN: Retrospective cross-sectional study...
March 2024: American Journal of Managed Care
https://read.qxmd.com/read/38434928/presentation-and-outcome-of-patients-with-multiple-myeloma-mm-single-centre-experience-from-windsor-essex-regional-cancer-centre
#14
JOURNAL ARTICLE
Dalia Kashash, Eric McArthur, Caroline Hamm, Rasna Gupta, Sindu Kanjeekal, Mohammad Jarrar, Lisa A Porter, John W Hudson, Adam Renaud, Indryas Woldie
INTRODUCTION: Outcomes for patients with multiple myeloma has significantly improved through the years. This is mainly related to the use of novel agents. METHODS: This is a retrospective study that reviewed presentation and outcome of 139 patients with multiple myeloma at the Windsor Essex Regional Cancer Centre from Jan. 1, 2015 to Dec. 31, 2019. Median age was 71 years and most patients had higher risk disease (65.5% either R ISS stage II or III). 30% had high risk FISH for myeloma including del...
2024: Journal of Blood Medicine
https://read.qxmd.com/read/38361983/dual-plating-in-the-metastatic-distal-humerus-benefits-may-outweigh-the-risks
#15
JOURNAL ARTICLE
William West, Andrew Moore, Caroline Gerhardt, Paul Webb, Odion Binitie, Alexander Lazarides, Douglas Letson, David Joyce
BACKGROUND: Impending and complete pathologic fractures of the distal humerus are rare complications of metastatic cancer. Surgical treatment aims to quickly restore function and minimize pain. Plate and screw fixation (PSF) is a common method for addressing these lesions, but unlike in orthopaedic trauma, there are no clear guidelines for best management. While dual PSF theoretically provides better support and reduces the chance of reoperation due to tumor progression, single PSF is currently the more common choice...
May 2024: Journal of Orthopaedics
https://read.qxmd.com/read/38361352/a-50-year-old-man-presenting-with-multiple-bone-lesions-and-a-diagnosis-of-phosphaturic-mesenchymal-tumor-of-the-femur
#16
JOURNAL ARTICLE
Dong Ren, Katherine Wei, Ibe Ifegwu
BACKGROUND Phosphaturic mesenchymal tumor (PMT) is an extremely rare mesenchymal neoplasm that is commonly seen in bone and soft tissue. It is associated with a paraneoplastic syndrome, oncogenic osteomalacia, due to tumor-induced urinary phosphate wasting. It is demonstrated to be predominantly mediated by fibroblast growth factor 23 (FGF23)/fibroblast growth factor receptor 1 (FGFR1) axis. Clinically, PMT usually presents as a solitary lesion in the bone. The diagnosis of PMT is challenging due to its non-specific clinical manifestation, radiologic findings, and morphological features...
February 16, 2024: American Journal of Case Reports
https://read.qxmd.com/read/38343457/efficacy-and-risk-of-osteonecrosis-of-the-jaw-for-pamidronate-zoledronic-acid-and-denosumab-in-comparison-to-alendronate-in-multiple-myeloma-patients
#17
JOURNAL ARTICLE
Micah Browne, Brittany Miles, James Mackey
BACKGROUND: Approximately 70% of multiple myeloma patients develop pathologic fractures. Osteoclast inhibitors can provide reduction in vertebral fractures with an increased risk of osteonecrosis of the jaw (ONJ). ONJ associated with currently used osteoclast inhibitors causes significant morbidity, often from delayed diagnosis and ineffective treatment. METHODS: The TriNetX Diamond Network was used to create patient cohorts for each medication: alendronate, pamidronate, zoledronic acid, and denosumab...
2024: Proceedings of the Baylor University Medical Center
https://read.qxmd.com/read/38335985/risk-of-fractures-in-half-a-million-survivors-of-20-cancers-a-population-based-matched-cohort-study-using-linked-english-electronic-health-records
#18
JOURNAL ARTICLE
Eva Buzasi, Helena Carreira, Garth Funston, Kathryn E Mansfield, Harriet Forbes, Helen Strongman, Krishnan Bhaskaran
BACKGROUND: A history of multiple myeloma, prostate cancer, and breast cancer has been associated with adverse bone health, but associations across a broader range of cancers are unclear. We aimed to compare the risk of any bone fracture and major osteoporotic fractures in survivors of a wide range of cancers versus cancer-free individuals. METHODS: In this population-based matched cohort study, we used electronic health records from the UK Clinical Practice Research Datalink linked to hospital data...
February 6, 2024: The Lancet. Healthy longevity
https://read.qxmd.com/read/38304318/transoral-balloon-kyphoplasty-in-a-myeloma-patient-with-painful-osseous-destruction-of-the-corpus-vertebrae-axis
#19
Julian Ramin Andresen, Harald Widhalm, Reimer Andresen
Multiple myeloma is the most common primary malignant disease of the spine, which can lead to pathological fractures with consecutive instability and immobilizing pain, due to osseous destruction of individual vertebral bodies. The different surgical care is challenging, although good stabilization should be achieved if possible. The resulting blocking of micro-movements leads to pain minimization. However, this is a symptomatic therapy and does not address the primary disease. In the following, we report on successful transoral balloon kyphoplasty for the treatment of myeloma-related osteolysis with a pathological fracture of vertebral body C2, which led to a significant clinical improvement...
January 2024: Journal of Surgical Case Reports
https://read.qxmd.com/read/38271550/treatment-of-an-impending-pathologic-sacral-fracture-with-a-novel-iliosacral-fusion-construct-a-case-report
#20
JOURNAL ARTICLE
Robert C Jacobs, David W Polly
CASE: A 49-year-old woman presented with left leg radiculopathy and posterior pelvic pain. Subsequent evaluation demonstrated metastatic multiple myeloma with an impending left S1 sacral fracture. Immediate posterior pelvic ring stabilization was recommended to prevent fracture and disruption of her oncologic recovery. This was performed percutaneously with computer-assisted navigation using a novel cannulated screw design. CONCLUSION: The patient was treated with prophylactic percutaneous posterior pelvic ring fixation with a novel cannulated screw design that provided a durable construct for immediate weight-bearing...
January 1, 2024: JBJS Case Connector
keyword
keyword
66225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.